Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

First Posted Date
2018-10-22
Last Posted Date
2024-10-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
794
Registration Number
NCT03713593
Locations
🇺🇸

Emory University Winship Cancer Institute ( Site 0639), Atlanta, Georgia, United States

🇺🇸

Beth Israel Deaconess Medical Center ( Site 0716), Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital ( Site 0603), Boston, Massachusetts, United States

and more 169 locations

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Completed
Conditions
Carcinoma, Hepatocellular
Interventions
Drug: Lenvatinib
First Posted Date
2018-09-10
Last Posted Date
2021-01-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
713
Registration Number
NCT03663114
Locations
🇯🇵

Eisai trial site 1, Osaka, Japan

🇯🇵

Eisai trial site 2, Tokyo, Japan

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

First Posted Date
2018-08-14
Last Posted Date
2021-07-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
6
Registration Number
NCT03630120
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Lenvatinib and Pembrolizumab Simultaneous Combination Study

Phase 2
Completed
Conditions
Advanced Gastric Cancer
Interventions
Drug: Lenvatinib
Drug: Pembrolizumab
First Posted Date
2018-08-01
Last Posted Date
2021-04-26
Lead Sponsor
National Cancer Center Hospital East
Target Recruit Count
29
Registration Number
NCT03609359
Locations
🇯🇵

NationalCCHE, Kashiwa, Tokyo, Japan

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Phase 4
Active, not recruiting
Conditions
Thyroid Neoplasms
Interventions
Drug: Lenvatinib
First Posted Date
2018-06-29
Last Posted Date
2024-09-30
Lead Sponsor
Eisai Pharmaceuticals India Pvt. Ltd
Target Recruit Count
50
Registration Number
NCT03573960
Locations
🇮🇳

Deenanath Mangeshkar Hospital, Pune, Maharashtra, India

🇮🇳

BL Kapoor Hospital, New Delhi, New Delhi, India

🇮🇳

Indrayani Hospital, Alandi, Pune, India

and more 7 locations

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

First Posted Date
2018-06-21
Last Posted Date
2024-11-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
442
Registration Number
NCT03564691
Locations
🇨🇦

Princess Margaret Cancer Centre ( Site 0033), Toronto, Ontario, Canada

🇺🇸

Seattle Cancer Care Alliance ( Site 0010), Seattle, Washington, United States

🇺🇸

University of California at San Francisco ( Site 0004), San Francisco, California, United States

and more 34 locations

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Conditions
Thyroid Cancer
First Posted Date
2018-05-23
Last Posted Date
2018-12-17
Lead Sponsor
Eisai Inc.
Registration Number
NCT03533361
Locations
🇧🇷

Hospital Sirio Libanes, Sao Paulo, São Paulo, Brazil

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

First Posted Date
2018-05-16
Last Posted Date
2024-11-25
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
30
Registration Number
NCT03526679
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

First Posted Date
2018-05-07
Last Posted Date
2024-11-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
318
Registration Number
NCT03516981
Locations
🇵🇱

Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw, Dolnoslaskie, Poland

🇨🇦

Jewish General Hospital ( Site 0307), Montreal, Quebec, Canada

🇺🇸

University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento, California, United States

and more 78 locations

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

First Posted Date
2018-05-07
Last Posted Date
2023-10-18
Lead Sponsor
Eisai Inc.
Target Recruit Count
827
Registration Number
NCT03517449
Locations
🇺🇸

North Shore University Health System, Evanston, Illinois, United States

🇺🇸

Greater Baltimore Medical Center, Baltimore, Maryland, United States

🇺🇸

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 159 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy